MapLight Therapeutics, Inc. (MPLT)
| Market Cap | 397.20M-50.7% |
| Revenue (ttm) | n/a |
| Net Income | n/a-148.6% |
| EPS | n/a-132.3% |
| Shares Out | 42.44M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 275,183 |
| Open | 9.62 |
| Previous Close | 9.69 |
| Day's Range | 9.33 - 9.88 |
| 52-Week Range | 8.92 - 40.43 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 29.20(+211.97%) |
| Earnings Date | n/a |
MapLight Therapeutics, Inc. has a live Insider Score.
Scored on 1 qualifying trade from 1 insider in the last 90 days.
About MPLT
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; ML-055 for the treatment of neuropsychiatric conditions; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. The company was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$MPLT stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in MPLT holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by MPLT's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
MPLT Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New MPLT patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to MPLT from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in MPLT
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $7.16M |
| IWMiShares Russell 2000 ETF | $3.16M |
| VXFVanguard Extended Market ETF | $2.82M |
| IWOiShares Russell 2000 Growth ETF | $1.03M |
| SCHASchwab U.S. Small-Cap ETF | $870.05K |
| VTWOVanguard Russell 2000 ETF | $774.56K |
Estimated from each fund’s disclosed top holdings × AUM
MPLT Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from MPLT’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score